Boston Therapeutics commences clinical trial for PAZ320 in diabetics
PAZ320 is a chewable complex carbohydrate-based compound designed to reduce post-meal elevation of blood glucose, as it blocks the action of carbohydrate-hydrolyzing enzymes. The trial will comprise adults
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.